S'abonner

Objective monitoring of nasal patency and nasal physiology in rhinitis - 18/08/11

Doi : 10.1016/j.jaci.2004.12.015 
Robert A. Nathan, MD a, , Ron Eccles, PhD, DSc b, Peter H. Howarth, BSc (Hons), DM, FRCP c, Sverre K. Steinsvåg, MD, PhD d, Alkis Togias, MD e
a From Asthma and Allergy Associates, Colorado Springs 
b Common Cold Centre, Cardiff School of Biosciences, Cardiff University 
c Southampton General Hospital 
d Department of Otorhinolaryngology, Sorlandet Hospital, Haukeland University Hospital, Kristiansand 
e Divisions of Clinical Immunology and of Respiratory and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore 

Reprint requests: Robert A. Nathan, MD, Asthma and Allergy Associates, 2709 North Tejon, Colorado Springs, CO 80907.

Colorado Springs, Colo, Cardiff and Southampton, United Kingdom, Kristiansand, Norway, and Baltimore, Md

Abstract

Nasal obstruction can be monitored objectively by measurement of nasal airflow, as evaluated by nasal peak flow, or as airways resistance/conductance as evaluated by rhinomanometry. Peak flow can be measured during inspiration or expiration. Of these measurements, nasal inspiratory peak flow is the best validated technique for home monitoring in clinical trials. The equipment is portable, relatively inexpensive, and simple to use. One disadvantage, however, is that nasal inspiratory peak flow is influenced by lower airway as well as upper airway function. Rhinomanometry is a more sensitive technique that is specific for nasal measurements. The equipment, however, requires an operator, is more expensive, and is not portable. Thus, it is applicable only for clinic visit measures in clinical trials. Measurements require patient cooperation and coordination, and not all can achieve repeatable results. Thus, this objective measure is best suited to laboratory challenge studies involving smaller numbers of selected volunteers.

A nonphysiological measure of nasal patency is acoustic rhinometry. This sonic echo technique measures internal nasal luminal volume and the minimum cross-sectional area. The derivation of these measures from the reflected sound waves requires complex mathematical transformation and makes several theoretical assumptions. Despite this, however, such measures correlate well with the nasal physiological measures, and the nasal volume measures have been shown to relate well to results obtained by imaging techniques such as computed tomography scanning or magnetic resonance imaging. Like rhinomanometry, acoustic rhinometry is not suitable for home monitoring and can be applied only to clinic visit measures or for laboratory nasal challenge monitoring. It has advantages in being easy to use, in requiring little patient cooperation, and in providing repeatable results.

In addition to nasal obstruction, allergic rhinitis is recognized to be associated with impaired mucociliary clearance and altered nasal responsiveness. Measures exist for the monitoring of these aspects of nasal dysfunction. Although measures of mucociliary clearance are simple to perform, they have a poor record of reproducibility. Their incorporation into clinical trials is thus questionable, although positive outcomes from therapeutic intervention have been reported. Measures of nasal responsiveness are at present largely confined to research studies investigating disease mechanisms in allergic and nonallergic rhinitis. The techniques are insufficiently standardized to be applied to multicenter clinical trials but could be used in limited-center studies to gain insight into the regulatory effects of different therapeutic modalities.

Le texte complet de cet article est disponible en PDF.

Key words : Rhinitis, nasal obstruction, nasal peak flow, rhinomanometry, acoustic rhinometry, mucociliary clearance, nasal responsiveness

Abbreviations used : a-min, CT, NAR, NPEF, NPIF, PAR, SAR


Plan


 Disclosure of potential conflict of interest: R. A. Nathan has consultant arrangements with Amgen, Altana, AstraZeneca, Aventis, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering/Key, Sepracor, and Viropharm; receives grants/research support from Abbott, Altana, Aventis, AstraZeneca, Bayer, Berlex, Boehringer Ingelheim, Bristol-Meyers Squibb, Ciba-Geigy, Dura, Forest, GlaxoSmithKline, Immunex, Janssen, Parke-Davis, Pfizer, 3-M Pharmaceuticals, Proctor & Gamble, Roberts, Sandoz, Sanofi, Schering/Key, Sepracor, Sterling, Tap Pharmaceuticals, Wallace, and Wyeth; and is a member of the Speakers' Bureau for AstraZeneca, Aventis, Genentech/Novartis, GlaxoSmithKline, Pfizer, and Schering/Key. R. Eccles—none disclosed. P. H. Howarth has been an advisory board member for AstraZeneca, GlaxoSmithKline, Sanofi-Aventis, and Altana. S. K. Steinsvag—none disclosed. A. Togias has consultant arrangements with AstraZeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Sanofi-Aventis; and is a member of the Speakers' Bureau for Genentech, Merck, Novartis, and Pfizer.
Guest Editor: Peter H. Howarth, BSc (Hons), DM, FRCP
Attribution of Sections:
Nasal peak flow: Robert A. Nathan, MD
Rhinomanometry: Ron Eccles, PhD, DSc
Acoustic rhinometry: Peter H. Howarth, BSc (Hons), DM, FRCP
Mucociliary clearance: Sverre K. Steinsvåg, MD, PhD
Nasal responsiveness: Alkis Togias, MD


© 2005  American Academy of Allergy, Asthma and Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 115 - N° 3S

P. S442-S459 - mars 2005 Retour au numéro
Article précédent Article précédent
  • Objective monitoring of nasal airway inflammation in rhinitis
  • Peter H. Howarth, Carl G.A. Persson, Eli O. Meltzer, Mikila R. Jacobson, Stephen R. Durham, Philip E. Silkoff
| Article suivant Article suivant
  • Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication
  • Anders Akerlund, Morgan Andersson, Jeffrey Leflein, Torben Lildholdt, Niels Mygind

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.